Zolbetuximab is a monoclonal antibody targeting Claudin 18.2 (CLDN18.2), mainly indicated for the treatment of advanced gastric cancer. The specific dosage of this drug must be determined under the guidance of a doctor, and arbitrary dosage adjustments should be avoided.
The recommended first dose for adult patients is 800 mg/m². The dose can be reduced to 600 mg/m² from the second administration onwards, and further reduced to 400 mg/m² after an interval of 3 weeks.
For patients who tolerate zolbetuximab well, the administration rate can be gradually increased 30-60 minutes after the start of administration. However, the specific rate must follow the guidance of a professional doctor.
The administration frequency is intravenous infusion for more than 2 hours every 2 weeks.

